Inventor · disambiguated record
Santosh C. Sinha
Also filed as: SINHA SANTOSH · SINHA SANTOSH C
42 granted patents·22 pending applications·83 citations·filing 2003–2023
96Inventor score
Top patents by PatentIndex Score
64 records- 0190US7902247B2Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptorsALLERGAN INC·Filed 2008·Granted Mar 8, 2011·12 cites·15 claims
- 0287US8063231B2Methods of treating alpha adrenergic mediated conditionsFANG WENKUI K·Filed 2009·Granted Nov 22, 2011·4 cites·1 claims
- 0384US8329918B2Selective alpha 2B/2C agonistsNGUYEN PHONG X·Filed 2010·Granted Dec 11, 2012·7 cites·2 claims
- 0482US8735438B2Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptorsSINHA SANTOSH C·Filed 2010·Granted May 27, 2014·5 cites·5 claims
- 0582US8071636B2Methods of treating alpha adrenergic mediated conditionsFANG WENKUI K·Filed 2009·Granted Dec 6, 2011·4 cites·17 claims
- 0682US7476673B2Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptorsALLERGAN INC·Filed 2004·Granted Jan 13, 2009·20 cites·38 claims
- 0781US9402912B2Antibiotic conjugates directly linked with steroid drugsALLERGAN INC·Filed 2014·Granted Aug 2, 2016·5 cites·9 claims
- 0880US2023062049A1Methods of treating alpha adrenergic mediated conditionsALLERGAN INC·Filed 2021·Application pending·0 cites
- 0979US9849113B2Methods of treating α adrenergic mediated conditionsALLERGAN INC·Filed 2017·Granted Dec 26, 2017·1 cites·5 claims
- 1079US9040532B2Alpha adrenergic receptor modulatorsCHOW KEN·Filed 2010·Granted May 26, 2015·4 cites·14 claims
- 1178US9402913B2Cyclosporine A steroid conjugatesALLERGAN INC·Filed 2014·Granted Aug 2, 2016·4 cites·2 claims
- 1278US8227499B2Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptorsSINHA SANTOSH C·Filed 2009·Granted Jul 24, 2012·2 cites·22 claims
- 1376US8124774B2Therapeutic ((phenyl)imidazolyl)methylquinolinyl compoundsSINHA SANTOSH C·Filed 2008·Granted Feb 28, 2012·2 cites·3 claims
- 1475US9623006B2Methods of treating α adrenergic mediated conditionsALLERGAN INC·Filed 2015·Granted Apr 18, 2017·1 cites·5 claims
- 1575US8530462B2Indole modulators of S1P receptorsSINHA SANTOSH C·Filed 2011·Granted Sep 10, 2013·2 cites·14 claims
- 1674US8426454B2Therapeutic compoundsSINHA SANTOSH C·Filed 2008·Granted Apr 23, 2013·1 cites·12 claims
- 1773US9034910B2Methods of treating alpha adrenergic mediated conditionsGIL DANIEL W·Filed 2011·Granted May 19, 2015·1 cites·17 claims
- 1872US8486969B2Therapeutic compoundsSINHA SANTOSH C·Filed 2008·Granted Jul 16, 2013·1 cites·11 claims
- 1971US2020330428A1Methods of treating alpha adrenergic mediated conditionsALLERGAN INC·Filed 2019·Application pending·0 cites
- 2070US8993553B2Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulatorsALLERGAN INC·Filed 2013·Granted Mar 31, 2015·1 cites·11 claims
- 2170US8492561B2Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulatorsSINHA SANTOSH C·Filed 2011·Granted Jul 23, 2013·1 cites·11 claims
- 2268US6683092B1[3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activityALLERGAN INC·Filed 2003·Granted Jan 27, 2004·4 cites·31 claims
- 2367US2010009985A1THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDSALLERGAN INC·Filed 2009·Application pending·0 cites
- 2467US2018344692A1Methods of treating alpha adrenergic mediated conditionsALLERGAN INC·Filed 2018·Application pending·0 cites
- 2565US2018071260A1Methods of treating alpha adrenergic mediated conditionsALLERGAN INC·Filed 2017·Application pending·0 cites
- 2664US2025368628A1Methods and compounds for modulating inherited genetic diseasesDESIGN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2763US8735399B2Selective subtype alpha 2 adrenergic agents and methods for use thereofHEIDELBAUGH TODD M·Filed 2009·Granted May 27, 2014·0 cites·11 claims
- 2862US9199989B2N—(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2014·Granted Dec 1, 2015·0 cites·9 claims
- 2962US8383646B2Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compoundsALLERGAN INC·Filed 2008·Granted Feb 26, 2013·0 cites·16 claims
- 3061US9034896B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2014·Granted May 19, 2015·0 cites·9 claims
- 3161US6936636B25-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activityALLERGAN INC·Filed 2003·Granted Aug 30, 2005·1 cites·42 claims
- 3260US8741921B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsALLERGAN INC·Filed 2013·Granted Jun 3, 2014·0 cites·9 claims
- 3360US8431702B2Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compoundsSINHA SANTOSH C·Filed 2012·Granted Apr 30, 2013·0 cites·8 claims
- 3459US8815861B2N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptorsSINHA SANTOSH C·Filed 2012·Granted Aug 26, 2014·0 cites·12 claims
- 3559US8513419B2N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptorsSINHA SANTOSH C·Filed 2012·Granted Aug 20, 2013·0 cites·11 claims
- 3659US8309729B2Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compoundsSINHA SANTOSH C·Filed 2012·Granted Nov 13, 2012·0 cites·4 claims
- 3758US8815923B2Therapeutic compoundsALLERGAN INC·Filed 2013·Granted Aug 26, 2014·0 cites·4 claims
- 3858US8188279B2Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compoundsSINHA SANTOSH C·Filed 2011·Granted May 29, 2012·0 cites·12 claims
- 3958US7432388B2Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activityALLERGAN INC·Filed 2007·Granted Oct 7, 2008·0 cites·4 claims
- 4056US8183414B2N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptorsCHOW KEN·Filed 2009·Granted May 22, 2012·0 cites·8 claims
- 4155US2022323626A1Compositions, Kits, Methods and Uses for Preventing Microbial GrowthCOLLIDION INC·Filed 2020·Application pending·0 cites
- 4255US2009182026A1Alpha 2 adrenergic agonistsALLERGAN INC·Filed 2006·Application pending·0 cites
- 4355US2024327439A1Pharmacological agents for preventing and treating cataracts and presbyopia eye diseasesPLEX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4454US8362022B2Selective subtype alpha 2 adrenergic agents and methods for use thereofALLERGAN INC·Filed 2009·Granted Jan 29, 2013·0 cites·6 claims
- 4554US7253319B2Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activityALLERGAN INC·Filed 2004·Granted Aug 7, 2007·0 cites·18 claims
- 4654US2025019352A1Pharmacological agents for treating ophthalmic diseasesPLEX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4753US8809379B2Selective subtype alpha 2 adrenergic agents and methods for use thereofHEIDELBAUGH TODD M·Filed 2009·Granted Aug 19, 2014·0 cites·2 claims
- 4853US2014206701A1Selective subtype alpha 2 adrenergic agents and methods for use thereofALLERGAN INC·Filed 2014·Application pending·0 cites
- 4952US8541397B2Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulatorsALLERGAN INC·Filed 2013·Granted Sep 24, 2013·0 cites·8 claims
- 5052US2009281322A1THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDSALLERGAN INC·Filed 2009·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Santosh C. Sinha files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →